Venture Kick

Clee Medical specializes in developing innovative neuroimaging and surgical access technologies to improve precision and efficiency in neurosurgery. Their products, which include imaging and sensing systems, provide enhanced access, vision, and navigation within the brain, seamlessly integrating with existing neurosurgical equipment and current surgical routines. This enables healthcare providers to potentially enhance patient outcomes with greater precision.

Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.

Scanvio develops AI-augmented ultrasound software for enhanced endometriosis diagnosis. It empowers gynecologists with expert sonography skills, aiming to improve healthcare outcomes and surgical education.

Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases

BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments

Translation-X is a biotechnology company specializing in the development of innovative therapeutics for Autism Spectrum Disorders (ASD). It employs a precision medicine strategy to target core symptoms of ASD, such as social interaction difficulties, aiming to provide effective treatment options for affected individuals.

ValTech Lifesciences is a medtech startup promoting cardiovascular health through its proprietary heart valve characteristics that improve the performance of mechanical and biological prostheses.

dEEGtal’s use of AI to expedite epilepsy diagnosis could make a significant difference in patient care, by analyzing EEG data quickly, it might help identify patterns or anomalies that could be missed by human reviewers alone.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.

Pace Locator is a medical technology company that specializes in developing advanced imaging software. Its flagship product, also named Pace Locator, uses electrocardiogram (ECG) and echocardiogram (ECHO) data to generate 3D maps of the heart. This innovative tool helps healthcare professionals localize the source of cardiac arrhythmias and visualize the location of cardiac implantable electronic device (CIED) leads, enabling faster and more accurate diagnoses.

HeroSupport is a medical device manufacturing company founded in 2019 and based in Veyrier, Geneva. The company specializes in creating medical immobilization devices designed to enhance patient comfort during clinical procedures. Its innovative technology transforms imaging and treatment tables into personalized support solutions, specifically catering to the needs of patients undergoing prone breast radiotherapy. This approach allows patients to benefit from tailored support, eliminating the need for them to adjust to the standard table. By improving patient comfort, HeroSupport enables healthcare providers to deliver more effective and cost-efficient cancer treatment.

AlpineWell developing novel solutions to hunger and swallowing difficulties, AlpineWell produces patient-centric food for special medicinal purposes (FSMP) and also provides automatic nutrition tracking to detect malnutrition early on.

Transpire Bio is a biotechnology platform focused on the development of inhaled therapeutics aimed at improving healthcare outcomes globally. The company specializes in the commercialization of lower-cost generic alternatives for injectable drugs, utilizing innovative delivery methods to enhance patient experience by providing painless administration. Transpire Bio's product portfolio includes medicines and inhalation therapies targeting both lung diseases and systemic conditions, reflecting its commitment to addressing a wide range of health challenges through advanced biopharmaceutical solutions.

Rhovica Neuroimaging specializes in innovative neuroimaging technology designed to optimize emergency treatment for patients with elevated intracranial pressure. Its primary product is a device that facilitates precise and rapid placement of external ventricular drains, enabling real-time monitoring post-insertion. This innovation aims to improve patient outcomes, reduce procedural complications, and potentially lower healthcare costs by streamlining critical neurological interventions.

Ocumeda operates a telemedical network of ophthalmologists, offering accessible eye examinations in collaboration with opticians, retirement homes, and companies. Their services include remote consultations and on-site assessments, enabling early detection and treatment of eye diseases to prevent vision loss.

Sensawear is a medical technology company that specializes in the production of wearable, textile-integrated sensors. These sensors monitor tissue oxygenation and skin pressure in real-time, alerting users to potential pressure injuries before they occur. By providing early warnings of low-oxygenation conditions caused by high-pressure points, Sensawear's products enable users to take preventative action, such as moving or being moved, thus minimizing the risk of painful and dangerous pressure ulcers.

SightIn Health develops artificial intelligence-powered software for portable ultrasound, providing image analytics, usage guidance, and interpretation to support patient diagnosis. The platform automates quality assessment, ultrasound probe guidance, and image analysis, lowering the skill barrier required to operate ultrasound equipment and capture medical images for diagnostics and prognostics. Founded in 2021 and based in Geneva, Switzerland, SightIn Health targets healthcare providers seeking accurate, AI-assisted medical image analysis.

Developer of a metabolic health assessment platform designed to support healthcare professionals in identifying at-risk individuals before traditional diagnostics. The company uses saliva-based metabolite measurements analyzed through customized Nuclear Magnetic Resonance (NMR) spectrometry, enabling registered nutritionists and healthcare providers to assess metabolic health with minimal invasiveness, competitive cost, and early detection capabilities.

FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on Endometriosis. The company aims to accelerate the path toward a cure for endometriosis by addressing significant healthcare requirements and advancing novel ideas in women's health. FimmCyte's mission is to empower women to take control of their health and meet their unmet medical needs through cutting-edge treatments.

Suri Biotech is a biotechnology company specializing in the development of targeted bacterial strains aimed at alleviating bloating and intestinal discomfort. Its proprietary strains reduce hydrogen gas production by intestinal microorganisms, with potential applications in various functional gastrointestinal disorders.

OptimaRatio liberates chronic and rare disease patients from managing their complex health data.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

Avelo focuses on saving lives through swift and precise infectious disease diagnoses in primary care settings. It specializes in manufacturing breath aerosol diagnostic equipment designed to enhance tuberculosis diagnosis via a non-invasive, painless breath collection device. This enables faster, accurate diagnoses using existing PCR testing infrastructure, facilitating earlier appropriate treatment and rapid patient referral.

YLAH is a technology company specializing in the development of web and mobile solutions for psychotherapists and their patients. Its core offerings include individualized therapy tools, clinical assessment platforms, and health monitoring systems, empowering therapists to efficiently scale their services using digital means.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Rhovica Neuroimaging specializes in innovative neuroimaging technology designed to optimize emergency treatment for patients with elevated intracranial pressure. Its primary product is a device that facilitates precise and rapid placement of external ventricular drains, enabling real-time monitoring post-insertion. This innovation aims to improve patient outcomes, reduce procedural complications, and potentially lower healthcare costs by streamlining critical neurological interventions.

Rhovica Neuroimaging specializes in innovative neuroimaging technology designed to optimize emergency treatment for patients with elevated intracranial pressure. Its primary product is a device that facilitates precise and rapid placement of external ventricular drains, enabling real-time monitoring post-insertion. This innovation aims to improve patient outcomes, reduce procedural complications, and potentially lower healthcare costs by streamlining critical neurological interventions.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Adaptyv Bio is a biotechnology company focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company's innovative technology aims to identify new antibodies for the treatment of various diseases by bridging the gap between computational predictions and experimental validation. Through its advanced methodologies, Adaptyv Bio seeks to enhance the efficacy of therapeutic interventions, ultimately improving patient outcomes.

Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.

Sensemodi develops a smart wearable that uses AI to analyze thermal, acoustic, and kinematic data to assess joint health. The device is designed to monitor knees and other joints with multiple sensor modalities, enabling users to check and track joint condition anywhere. By providing quick assessments and ongoing monitoring, Sensemodi aims to help prevent disability and reduce the socioeconomic burden of musculoskeletal disorders and support improved healthcare treatment.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Bottneuro is a company focused on developing innovative therapies for early to moderate-stage Alzheimer's Disease patients. Utilizing its proprietary NENI technology platform, Bottneuro creates non-invasive stimulation protocols that target neurons and glial cells in the brain. In addition to its work in Alzheimer's treatment, the company has developed a brain therapy system designed to alleviate chronic neuropathic pain. This system employs plant-based components and features a 3D printed cap that allows for continuous monitoring and targeted delivery of active substances within the body. By addressing the specific needs of patients with early to mild Alzheimer's disease, Bottneuro aims to enhance their quality of life through improved treatment options and medical care.

ArcoScreen is a Swiss medtech company developing a microfluidic discovery platform for drug screening that targets membrane receptors, notably G-protein coupled receptors. The platform blends a lab-on-chip system with biological assays to quantify GPCR activation in primary mammalian cells, including guanosine 5'-O-(3-thiotriphosphate)-based functional readouts, and supports both ready-to-use and custom stable cell lines. This approach enables pharmaceutical researchers to investigate receptor signaling, identify drug modes of action, and perform in-vitro screenings directly on patient-derived cells. By enabling faster, more predictive screenings, ArcoScreen aims to reduce clinical attrition and accelerate the development of therapeutic candidates with improved translational relevance.

Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.

Founded in 2020, Resmonics is a spin-off from ETH Zürich and University St. Gallen. It specializes in acoustic artificial intelligence that analyzes room soundscapes to detect symptoms of infectious lung diseases. Its product line, Quorum, combines this AI with air quality sensors and noise analytics to create healthy work environments.

CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.

Aseptuva is an early-stage MedTech company based in Technopark Winterthur. It aims to combat Healthcare-Associated Infections (HAI) by developing medical devices for in-situ disinfection of various catheters, preventing infections at their source and potentially saving thousands of lives annually.

Axentless develops software using advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims.

CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.

Founded in Lausanne in 2019 by Théo-Tim Denisart and Roberto Costa, Helvitek Labs develops innovative anti-pollution face masks. Initially inspired by pollution experiences in China, the company aims to improve comfort and protection for health professionals using AI-driven sealing technology.

LifeMatrix is a biotechnology company focused on the development of biomimetic implants and bio-engineering technologies aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company specializes in human cell-derived, off-the-shelf tissue-engineered implants that integrate with the patient's body post-implantation, allowing them to grow and regenerate. This innovative approach addresses the limitations of traditional implants, promoting faster recovery and improved outcomes for patients. LifeMatrix's technology is supported by over 20 years of research, resulting in more than 100 peer-reviewed publications and extensive preclinical studies demonstrating safety and efficacy, paving the way for clinical applications. The company's advancements are bolstered by various national and international research grants, reflecting its commitment to transforming the field of regenerative medicine.

Founded in 2020, Emovo Care is a Swiss medical device company specializing in robotic orthoses for individuals with hand motor impairments, particularly those resulting from stroke. Their flagship product is an active orthosis that enables hemiparetic stroke patients to regain hand movement at home.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Nutrix is a Swiss health-technology company focused on prevention and precision medicine. It develops a non-invasive nanosensor placed on the tooth to measure glucose levels in saliva, with data transmitted to an external application. The sensor tracks food intake and provides dietary guidance to help prevent diabetes. The company combines artificial intelligence with wearables and human care to deliver cost-effective prevention and healthcare programs, including digital coaching and telemedicine, enabling caregivers to monitor patients remotely and reduce routine doctor visits. In 2025 Nutrix expanded its offering with CortiSense, a cortisol monitoring sensor, reflecting its move into non-invasive hormonal monitoring. Based in Basel, Switzerland, Nutrix provides an integrated solution of sensors, software, and care services.

Flowbone develops and promotes an injectable biomaterial for minimally invasive augmentation of fragile bones at high risk of fracture. Its treatment strengthens bone without impeding mechanics or blood flow, aiming to improve independence and quality of life among the elderly by preventing fragility fractures.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

Founded in 2020, SurgeonsLab specializes in developing patient-specific training models for surgical procedures. It offers microsurgical treatment planning, procedure planning, and validation of new medical devices to enhance precision and safety in surgeries.

EarlySight, a Lausanne-based medical device company, develops technology to detect and treat eye diseases at an early stage. Its flagship work includes a fundus camera that images the retina with high detail by combining eye illumination with real time ocular aberration correction. The company also leverages cellular level imaging and transscleral illumination to monitor day to day treatment effects in a non invasive manner, enabling eye specialists to visualize the morphology of retinal cells. Founded in 2016, EarlySight aims to bring its imaging technology to clinics to improve early diagnosis and treatment of ocular conditions.

Inanna develops a clinical decision assistance platform designed to enhance outcomes in in-vitro fertility treatments. The platform employs machine learning algorithms and a global patient database to offer data-driven insights for personalized treatment recommendations, adaptively adjusted based on each patient's medical history and response.

Terapet specializes in advanced proton therapy for cancer treatment. Founded by physicists Christina Vallgren, Marcus Palm, and Professor Raymond Miralbell from Geneva University Hospitals, the company offers precise radiotherapy that minimizes harm to healthy cells. Incorporated in 2019, Terapet is based in Geneva, Switzerland.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

Testmate Health is a medtech startup and award-winning spin-off of the University of Geneva in Switzerland. It has developed a smartphone-compatible platform test kit capable of diagnosing diseases based on identifiable DNA or RNA sequences without the need for a laboratory, delivering results in minutes at home. The initial product is a rapid urine self-test for the four most common sexually transmitted infections, designed to be used outside clinical settings and to provide a smartphone-scanable result that supports immediate access to treatment if needed. The platform uses DNA isothermal technology to detect infectious diseases with identifiable DNA, enabling home testing without laboratory submission. Further test kits for additional diseases are in development to empower users to monitor their health from home.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Founded in 2019, Swiss Medical Union specializes in developing and manufacturing advanced bioreactor systems for testing new medical products' interaction, efficiency, and safety using human organ and tissue models. The company offers a software suite to simulate organ activity, analyze product-organ interactions, and monitor effects in real-time. Additionally, they provide clinical testing services to hospitals, healthcare institutions, and international facilities.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Autonomyo is a Swiss company founded in 2014, based in Lausanne, that specializes in developing robotic rehabilitation solutions for individuals with neurological gait disorders. The company focuses on manufacturing a lightweight exoskeleton designed to facilitate robotically assisted gait training, which can be utilized in rehabilitation clinics as well as in home settings with remote monitoring capabilities. Autonomyo's team, comprised of engineers, developers, and healthcare professionals, is dedicated to enhancing accessibility and training intensity for people with neuromuscular and motor disorders, ultimately aiming to improve their mobility and restore their freedom of movement.

C-MedTec is a company focused on enhancing the detection and monitoring of brain concussions through innovative technology. It has developed a specialized helmet that serves as a medical imaging modality capable of measuring brain metabolism and identifying abnormal neurological behavior following a traumatic impact. This advancement addresses the significant gap in concussion diagnosis, which traditionally relies on subjective assessments by trained professionals. By providing early detection and diagnosis, C-MedTec aims to promote safer sports practices and mitigate the risk of long-term effects and chronic conditions such as Alzheimer's disease and chronic traumatic encephalopathy (CTE). Through its cutting-edge approach, the company seeks to improve health outcomes for athletes and individuals at risk of brain trauma.

Galventa is a company dedicated to improving sleep and wakefulness through innovative technological solutions. They specialize in developing clinically tested galenic platform technologies designed to enhance sleep quality and mitigate symptoms of sleep inertia. Their primary product is a food supplement based on micro-pellets, engineered to create time-controlled release systems. This supplement aims to regulate the sleep-wake cycle and synchronize the circadian clock, helping individuals with sleep inertia align their sleep patterns with their daily routines.

KOVE is a medical technology company focused on prenatal care. It has developed an implantable device that closes and secures the hole created by endoscopes in the fetal membrane during fetoscopy, preventing membrane rupture. By reducing this procedure-related risk, the device enables doctors to perform more fetal treatments during pregnancy and lowers the chance of preterm birth. Described as a medtech spin-off, KOVE aims to advance prenatal procedures by mitigating complications associated with fetal interventions.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Artiria Medical develops innovative guidewire systems designed to enhance navigation during neurovascular procedures. Its products feature dynamic tip deflection, superior torque transmission, a high-quality hydrophilic coating, smooth intravascular navigation, adjustability, and a controlled tip deflection mechanism. These devices aim to facilitate complex interventions, reduce procedure-related risks, and improve overall efficiency.

Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.

KaleiBox is a company based in Zurich, Switzerland, specializing in the development of three-dimensional optical imaging devices specifically designed for small-animal imaging. It offers two main products: the standalone-mode KaleiBox and a hybrid-mode KaleiBox, both of which facilitate fluorescence tomography with an emphasis on compact hardware design and advanced software. The company's devices serve various applications, including research laboratories, biotechnological industries, agricultural diagnostics, and image-guided surgical procedures. Drawing inspiration from the kaleidoscope, KaleiBox focuses on versatility and portability, aiming to enhance the current workflow in 3D fluorescence imaging, particularly for preclinical studies.

Auxivo AG is a Swiss company based in Zürich that specializes in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing the physical strain and fatigue associated with such work, Auxivo's products aim to enhance worker safety and well-being, ultimately minimizing the risk of injuries. The company's focus on creating accessible exoskeletons underscores its commitment to improving workplace conditions and ensuring the long-term health of its users.

OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.

OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.

Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

KOVE is a medical technology company focused on prenatal care. It has developed an implantable device that closes and secures the hole created by endoscopes in the fetal membrane during fetoscopy, preventing membrane rupture. By reducing this procedure-related risk, the device enables doctors to perform more fetal treatments during pregnancy and lowers the chance of preterm birth. Described as a medtech spin-off, KOVE aims to advance prenatal procedures by mitigating complications associated with fetal interventions.

Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Artiria Medical develops innovative guidewire systems designed to enhance navigation during neurovascular procedures. Its products feature dynamic tip deflection, superior torque transmission, a high-quality hydrophilic coating, smooth intravascular navigation, adjustability, and a controlled tip deflection mechanism. These devices aim to facilitate complex interventions, reduce procedure-related risks, and improve overall efficiency.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

Hi-D Imaging AG is a Swiss company established in 2019, specializing in advanced imaging technologies for cardiovascular disease, particularly focusing on heart valve replacement. The company offers a SaaS-based pre-operational planning platform that assesses the hemodynamics of patient-specific anatomies. This platform enables physicians to analyze blood flow patterns and select the optimal size and shape of heart valves prior to trans-catheter aortic valve implantation. By providing detailed imaging and in-vitro fluid dynamic analysis, Hi-D Imaging empowers medical professionals to make data-driven decisions tailored to individual patient needs, thereby improving surgical outcomes and reducing the necessity for additional medical imaging. The company is headquartered in Winterthur, Switzerland.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Auxivo AG is a Swiss company based in Zürich that specializes in the development and manufacturing of wearable exoskeletons. These innovative devices are designed to support and protect workers engaged in physically demanding tasks, such as lifting and carrying heavy objects. By reducing the physical strain and fatigue associated with such work, Auxivo's products aim to enhance worker safety and well-being, ultimately minimizing the risk of injuries. The company's focus on creating accessible exoskeletons underscores its commitment to improving workplace conditions and ensuring the long-term health of its users.

b-rayZ is a spin-off from University Hospital Zurich that develops artificial intelligence tools for medical imaging. Its team blends radiologists, data scientists and physicians with extensive experience in imaging and radiology. The company creates predictive deep learning analytics to assess personal medical images and to support radiologists in mammography by providing real-time image quality and breast density assessments. The software enables standardized evaluation of imaging data to improve breast cancer detectability and aims to enhance diagnostic accuracy and efficiency, potentially reducing healthcare costs.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Artiria Medical develops innovative guidewire systems designed to enhance navigation during neurovascular procedures. Its products feature dynamic tip deflection, superior torque transmission, a high-quality hydrophilic coating, smooth intravascular navigation, adjustability, and a controlled tip deflection mechanism. These devices aim to facilitate complex interventions, reduce procedure-related risks, and improve overall efficiency.

Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.

KOVE is a medical technology company focused on prenatal care. It has developed an implantable device that closes and secures the hole created by endoscopes in the fetal membrane during fetoscopy, preventing membrane rupture. By reducing this procedure-related risk, the device enables doctors to perform more fetal treatments during pregnancy and lowers the chance of preterm birth. Described as a medtech spin-off, KOVE aims to advance prenatal procedures by mitigating complications associated with fetal interventions.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.